xWatts, a University of Cambridge spin-out, is developing an intelligent energy management software that reduces costs and emissions by 30% in large commercial buildings via autonomation and predictive control. With minimal user intervention, the company’s software automates and controls all isolated processes, such as operations, heating, cooling or storage.
The Enterprise Investment Scheme (EIS) is a useful tax planning tool for investors to take advantage of 5 generous tax benefits*, as well as investing in some of the brightest minds and world-changing innovations in the UK. Our CEO, Moray Wright, and FT Adviser discuss the opportunities the scheme has to offer and its increasing
As we approach Tax Year end, there has never been a more compelling time to understand the value of the Enterprise Investment Scheme (EIS). Our CEO, Moray Wright, and Professional Adviser, sheds light on how EIS is making a significant impact on the UK, with 33,000 companies supported and £23bn invested. The scheme offers investors
From waste plastic transformation to a smart fitness device for the brain, the Founders at the University of Cambridge Start 1.0 accelerator has announced 11 start-ups selected for the programme. As an Investment Partner, we are delighted to see these Cambridge companies receive funding, mentorship and development work. Cambridge, 12 March 2024: Founders at the
On the 6th of March 2024, Parkwalk and IP Group’s Women’s Networking Group hosted a panel discussion at their offices to celebrate International Women’s Day (IWD), with the IWD 2024 theme of ‘inspire inclusion’, and the next generation of female Non-Executive Directors and Board members. The theme of International Women’s Day 2024 is inspire inclusion, so
In a recent interview with IFA/GBI magazine, Parkwalk CEO Moray Wright discusses the most significant growth opportunities for investment, the most common risks for investors and explains Parkwalk’s investment strategy. Read the full interview on IFA magazine. What tax-efficient schemes does your company work with, and how do you offer a unique/compelling approach for advisers?
This page is designed for use by St. James’s Place Partners only. Here you will find the latest Parkwalk fund(s) literature to download. Parkwalk Current Open Funds this tax year Contact Information For any questions about our current Open Funds, please contact Susie Harris or Harriet Doherty on
[email protected] or 020 7062 9835. About Parkwalk
Delighted to announce our investment into adsilico as part of a £3.5m seed funding round, as seen in The Times today. The University of Leeds spin-out is a ground-breaking computational medicine company, developing an end-to-end in-silico trials solution based on virtual ‘synthetic’ patient populations. This investment will fund the essential development in adsilico whilst building the
adsilico is developing an end-to-end in-silico trials solution based on virtual ‘synthetic patient populations that will provide better and safer medical devices earlier to patients, reduce costs and accelerate R&D timescales for medical device developers, contribute to animal welfare by reducing animal experimentation, reducing refining and partially replacing costly and potentially harmful human trials.
Thrilled to announce our latest investment into Echopoint Medical as part of a £4.2m series A funding round. The University College London spin-out has designed an advanced diagnostic solution for cardiovascular care to improve patient outcomes. This funding round will help the company’s flagship iKOr system through the FDA approval process, setting the stage for
Koalaa is developing the next generation of prosthetics and orthotics for people with upper limb differences. The Imperial College London spin-out has designed a range of comfortable, affordable, and functional prosthetics with modular tools that can clip into the sleeve and be used for specific tasks.
Albus Health has developed a passive, contactless home monitoring device that tracks biomarkers such as respiratory rate in patients while they are asleep without disturbing them. The device also captures environmental metrics, such as air quality, humidity and temperature.
Thrilled to announce our latest investment into Wayland Additive as part of a £4.2m funding round. Wayland is a Huddersfield-based company providing electron beam, 3D printing technology using Calibur3 metal additive manufacturing (AM) machines and will use the funding to improve in-house production capability and increase their global customer base. Wayland Additive, the electron beam
We are delighted to announce the launch of our Imperial College Enterprise Fund (ICEF) III. The Fund is managed by Parkwalk in conjunction with Imperial Enterprise. The Fund invests in early-stage hard science and disruptive technology companies, linked to Imperial College, one of the world’s top 10 ranked universities. Tuesday 16 January 2024, London: Parkwalk
In general, 2023 was a challenging year for venture capital, with continuing macro-economic uncertainties and a volatile geopolitical backdrop, as well as the interest rate cycle adversely impacting the sector. There were, however, some positives for the UK-specific sector last year, with the EIS and VCT Sunset clause being extended to 2035, which is good
After fifteen years at the helm of Parkwalk, Alastair Kilgour has decided to step back from being Chief Investment Officer with effect from the end of December 2023. He will, of course, remain a Founder of Parkwalk and will spend several months handing over the role and responsibilities to John Pearson, who will be taking
Parkwalk are thrilled to have won ‘Best EIS Investment Manager’ at the Growth Investor Awards 2023, for the second year running. The judges recognised our returns to our investors and our unique strategy investing into cutting-edge technologies spinning out of top UK universities and research institutions. Now in their 9th year, the Growth Investor Awards
Along with 100 experts from Graphcore, Arm, Google and Stripe, we are proud to support the Founders at the University of Cambridge, with Cambridge Enterprise, aiding the next generation of start-ups. This new initiative is the first pre-seed accelerator for the University and as part of the first 12-week programme, up to 10 early-stage companies
MeVitae has developed software to streamline recruitment processes, using data-driven technology to attract, screen and retain top talent whilst building diverse and productive teams fairly. The software aims to eliminate 15 bias parameters using its suite of Artificial Intelligence-based solutions.
We are pleased to announce the launch of the Parkwalk Knowledge Intensive EIS Fund III, an HMRC-approved EIS Fund. As featured in Investment Week, the third Knowledge Intensive Fund will back cutting-edge technology companies spun out of leading UK universities and research institutions, mirroring the investment strategy of our Opportunities EIS Fund. Parkwalk Advisors, the
